TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18001585

Group type: EXPERIMENTAL
Intervention: 1.23% fluoride foam
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 392
Study: 15533485

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 2 g three times daily on the day of and the first day after the operation
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control
Number of subjects: 136
Study: 11403540

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists (cimetidine or ranitidine) or proton pump inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipase (at least 90,000 USP units) taken with acid suppression agents
Number of subjects: 0
Study: 9740281

Group type: EXPERIMENTAL
Intervention: Tetracycline (500 mg qid in adults and 12.5 mg/kg qid in children) for 3 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Norfloxacin (400 mg bid in adults and 7.5 mg/kg bid in children) for 3 days
Number of subjects: 25
Study: 8035693

Group type: EXPERIMENTAL
Intervention: Naming color words
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked lists of color patches
Number of subjects: 0
Study: 2655906

Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg three times daily for four weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31043158

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 67
Study: 28291486

Group type: EXPERIMENTAL
Intervention: Nurse Health Coaching (NHC)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Herbal Supplementation
Number of subjects: 435

Group type: COMPARATOR
Intervention: Control group (Army MOVE!)
Number of subjects: 435
Study: 25358652

Group type: EXPERIMENTAL
Intervention: Community Treatment By Experts (CTBE) with combined treatment model (SFT and DBT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 45
Study: 22748946

Group type: EXPERIMENTAL
Intervention: Telephone follow-up intervention
Number of subjects: 11
Study: 21397400

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study: 19772451

Group type: EXPERIMENTAL
Intervention: AIR inhaled insulin
Number of subjects: 560

Group type: COMPARATOR
Intervention: Insulin glargine (IG)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: AIR inhaled insulin plus intensified insulin glargine (AIR + IG)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: AIR + IG
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: AIR alone
Number of subjects: 560

Group type: COMPARATOR
Intervention: IG alone
Number of subjects: 560
Study: 16990198

Group type: EXPERIMENTAL
Intervention: 5 g NaCl per day for one week
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (no sodium chloride) per day for one week
Number of subjects: 10
Study: 15570201

Group type: EXPERIMENTAL
Intervention: 1.5 g intravenous cephalosporin (antibiotic prophylaxis)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 1008
Study: 11093066

Group type: EXPERIMENTAL
Intervention: G2457A polymorphism in ABCG1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Replication study with independent patients and controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suicidal behavior
Number of subjects: 0
Study: 9211437

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (30 mg p.o.)
Number of subjects: 40
Study: 8350608

Group type: EXPERIMENTAL
Intervention: Exercise (EX) - 5 sessions of 45 min brisk walking/week at 62 +/- 2% VO2max for 15 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-exercise (NEX) - Control group
Number of subjects: 36
Study: 3784305

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2-D3 treatment
Number of subjects: 5

Group type: COMPARATOR
Intervention: Aluminum containing antacids
Number of subjects: 5

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30057064

Group type: EXPERIMENTAL
Intervention: Relaxation exercises for four weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard cares
Number of subjects: 84
Study: 27843700

Group type: EXPERIMENTAL
Intervention: Passive observation of a 1-min video depicting the task performed at 3 Hz
Number of subjects: 65

Group type: COMPARATOR
Intervention: Black screen (control group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: fMRI signal in the left primary motor strip during passive video observation
Number of subjects: 65
Study: 24893290

Group type: EXPERIMENTAL
Intervention: Smoking cessation (abstainers)
Number of subjects: 1504

Group type: COMPARATOR
Intervention: Continuing smoking (control group)
Number of subjects: 1504
Study: 23513463

Group type: EXPERIMENTAL
Intervention: TEAS+AA
Number of subjects: 40

Group type: COMPARATOR
Intervention: AA
Number of subjects: 40
Study: 20219602

Group type: EXPERIMENTAL
Intervention: IAN block with 1.8 mL of Lidocaine 2% with 1:80,000 epinephrine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: IAN block with 3.6 mL of Lidocaine 2% with 1:80,000 epinephrine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: IAN block with 1.8 mL and buccal infiltration with 1.8 mL of Lidocaine 2% with 1:80,000 epinephrine
Number of subjects: 84
Study: 18567536

Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic stimulation (STN stimulation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No stimulation (OFF)
Number of subjects: 12
Study: 15834325

Group type: EXPERIMENTAL
Intervention: Information Group (nonelastic sacroiliac belt and oral/written information about pelvic girdle pain)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Home Exercise Group (nonelastic sacroiliac belt, oral/written information, and home exercise program)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: In Clinic Exercise Group (nonelastic sacroiliac belt, oral/written information, and participation in a training program)
Number of subjects: 118
Study: 12425844

Group type: EXPERIMENTAL
Intervention: Pre-operation-education (1 hour of educational video and clinic environment familiarization)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Local anesthesia (1.8 ml of 2% lidocaine injected 15 minutes before treatment)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Blank control (no intervention)
Number of subjects: 150
Study: 10805067

Group type: EXPERIMENTAL
Intervention: Problem-based pharmacotherapy training
Number of subjects: 111

Group type: COMPARATOR
Intervention: Pre-test results
Number of subjects: 111

Group type: COMPARATOR
Intervention: Basic knowledge about drugs
Number of subjects: 111
Study: 8678631

Group type: EXPERIMENTAL
Intervention: Hypothermic CPB (rectal temperature, 27 degrees C to 28 degrees C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normothermic CPB (rectal temperature, more than 35 degrees C)
Number of subjects: 30
Study: 1864299

Group type: EXPERIMENTAL
Intervention: Quinolones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-dose prophylaxis
Number of subjects: 0
Study: 7060323

Group type: EXPERIMENTAL
Intervention: 10 mg verapamil intravenously
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 80 mg verapamil orally
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 120 mg verapamil orally
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 160 mg verapamil orally
Number of subjects: 20
Study: 30409780

Group type: EXPERIMENTAL
Intervention: Aldosterone levels in response to angiotensin-II infusion
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Rest myocardial blood flow (MBF)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Diastolic function
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Correlation of rest MBF with diastolic function
Number of subjects: 73
Study: 28292758

Group type: EXPERIMENTAL
Intervention: Fasted condition
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fed condition
Number of subjects: 10
Study: 25773888

Group type: EXPERIMENTAL
Intervention: PhyS-milk (1.57 g PhyS in 250 ml/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ω3-milk (375 mg ω3 in 250 ml/day)
Number of subjects: 32
Study: 23462922

Group type: EXPERIMENTAL
Intervention: Water pipe smoking (average of 3 sessions)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cigarette smoking (11 cigarettes per day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Water pipe smoking
Number of subjects: 13
Study: 21569373

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy following the CAPOX treatment scheme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 19098490

Group type: EXPERIMENTAL
Intervention: IL-2 with HAART interruption
Number of subjects: 41

Group type: COMPARATOR
Intervention: Continuous HAART
Number of subjects: 41
Study: 16837878

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 12174697

Group type: EXPERIMENTAL
Intervention: Educational group (structured educational programme)
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Normal General Advice group (usual advice from general practitioners)
Number of subjects: 1230
Study: 10443725

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 8652237

Group type: EXPERIMENTAL
Intervention: Epirubicin-vindesine (EV)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Mitoxantrone-vindesine (MV)
Number of subjects: 295
Study: 2189187

Group type: EXPERIMENTAL
Intervention: Salk killed virus vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 375685

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 7044523

Group type: EXPERIMENTAL
Intervention: Tamoxifen and aminoglutethimide combination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 20
Study: 29239252

Group type: EXPERIMENTAL
Intervention: Single-bundle reconstruction
Number of subjects: 12

Group type: COMPARATOR
Intervention: Double-bundle reconstruction
Number of subjects: 12
Study: 30514362

Group type: EXPERIMENTAL
Intervention: TAS followed by ALND and regional nodal irradiation excluding the dissected axilla
Number of subjects: 1500

Group type: COMPARATOR
Intervention: TAS followed by regional nodal irradiation including the full axilla
Number of subjects: 1500
Study: 26908796

Group type: EXPERIMENTAL
Intervention: Arterolane Maleate-Piperaquine Phosphate (AM-PQP)
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Artemether-Lumefantrine (A-L)
Number of subjects: 1072
Study: 24406207

Group type: EXPERIMENTAL
Intervention: Drug Conservation (DC) treatment strategy
Number of subjects: 1444

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1444

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 1444

Group type: EXPERIMENTAL
Intervention: Past smoking
Number of subjects: 1444

Group type: EXPERIMENTAL
Intervention: History of diabetes
Number of subjects: 1444

Group type: COMPARATOR
Intervention: Control group: Viral Suppression (VS) treatment strategy
Number of subjects: 1444
Study: 22835490

Group type: EXPERIMENTAL
Intervention: Rectocele repair surgery
Number of subjects: 160
Study: 20379093

Group type: EXPERIMENTAL
Intervention: Lafutidine (20mg)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Famotidine (40mg)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336

Group type: COMPARATOR
Intervention: Lafutidine vs Placebo
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Judging panels evaluation
Number of subjects: 336
Study: 17568759

Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 15475601

Group type: EXPERIMENTAL
Intervention: Leg crossing
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Muscle tensing
Number of subjects: 88
Study: 12060477

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnetic resonance spectroscopy (MRS)
Number of subjects: 0
Study: 10402156

Group type: EXPERIMENTAL
Intervention: Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI) after administration of sedatives (alcohol, triazolam, flunitrazepam)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI) after administration of stimulants (cocaine)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI) after administration of opioids (morphine, pentazocine, naloxone)
Number of subjects: 4
Study: 7595718

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms twice daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 49
Study: 2341774

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 7001898

Group type: EXPERIMENTAL
Intervention: Drug treatment with hydrochlorothiazide, with possible addition of alphamethyldopa or propranolol if needed.
Number of subjects: 785

Group type: COMPARATOR
Intervention: Control group (no drug treatment).
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Drug treatment group (with diastolic blood pressure >= 100 mm Hg before randomization).
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Drug treatment group.
Number of subjects: 785
Study: 31729126

Group type: COMPARATOR
Intervention: Blood pressure lowering medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive glucose control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 0
Study: 31430295

Group type: EXPERIMENTAL
Intervention: Mid-value offers in the ultimatum game (UG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Unfair offers in the ultimatum game (UG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fair offers in the ultimatum game (UG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mid-value offers in the dictator game (DG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Unfair offers in the dictator game (DG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fair offers in the dictator game (DG)
Number of subjects: 28
Study: 28884732

Group type: EXPERIMENTAL
Intervention: Intense massage of asymmetric chest zones (n=47)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Classical chest massage (n=46)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Manual therapy (n=44)
Number of subjects: 137
Study: 26050626

Group type: EXPERIMENTAL
Intervention: Active video games (AVGs) on the Xbox Kinect, 6 sessions of 50 minutes each
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no active video games)
Number of subjects: 36
Study: 24650825

Group type: EXPERIMENTAL
Intervention: Internet-based screening and brief intervention via eScreen.se
Number of subjects: 202

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: eScreen.se users
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 202
Study: 21367545

Group type: EXPERIMENTAL
Intervention: 16 g of ethanol daily (females)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 32 g of ethanol daily (males)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Abstinent (no ethanol consumption)
Number of subjects: 44
Study: 19581223

Group type: EXPERIMENTAL
Intervention: Dry heat application
Number of subjects: 136

Group type: COMPARATOR
Intervention: Moist heat application
Number of subjects: 136
Study: 17470012

Group type: EXPERIMENTAL
Intervention: graft + PRP
Number of subjects: 25

Group type: COMPARATOR
Intervention: graft alone (beta‐TCP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: graft + PRP + membrane
Number of subjects: 25
Study: 15023462

Group type: EXPERIMENTAL
Intervention: Fast formulation of starch acetate-diltiazem tablets
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moderate formulation of starch acetate-diltiazem tablets
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Slow formulation of starch acetate-diltiazem tablets
Number of subjects: 8

Group type: COMPARATOR
Intervention: Commercial reference tablet
Number of subjects: 8
Study: 12084445

Group type: COMPARATOR
Intervention: PSP patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: CBD patients
Number of subjects: 36
Study: 9802147

Group type: EXPERIMENTAL
Intervention: Hospital organised preventive intervention
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 106

Group type: COMPARATOR
Intervention: No intervention (usual follow-up)
Number of subjects: 106
Study: 7638765

Group type: EXPERIMENTAL
Intervention: Continuous force of 50 cN (approximately 50 g)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Continuous force of 100 cN (approximately 100 g)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Continuous force of 200 cN (approximately 200 g)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Interrupted type of force of 50 cN (approximately 50 g)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Retention after 8 weeks
Number of subjects: 144
Study: 2677862

Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin plus oral erythromycin
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 371316

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Post-operative perfusion scanning
Number of subjects: 43
Study: 30933857

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month dual-antiplatelet therapy (DAPT)
Number of subjects: 2

Group type: COMPARATOR
Intervention: 12-month ticagrelor-based DAPT
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month DAPT
Number of subjects: 2
Study: 28146136

Group type: EXPERIMENTAL
Intervention: Red meat consumption
Number of subjects: 1038

Group type: COMPARATOR
Intervention: PUFA or PUFA-rich oils
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Soy intake
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Fish intake
Number of subjects: 1038
Study: 25313429

Group type: EXPERIMENTAL
Intervention: Colorblind diversity message
Number of subjects: 539

Group type: COMPARATOR
Intervention: Multicultural diversity message
Number of subjects: 539
Study: 23379922

Group type: EXPERIMENTAL
Intervention: Standard or firm wire applied routinely on entry into transverse colon
Number of subjects: 112

Group type: COMPARATOR
Intervention: Unaided colonoscope
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Standard or firm wire
Number of subjects: 112
Study: 20974598

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 18474737

Group type: EXPERIMENTAL
Intervention: Diffusion tensor tractography analysis of fiber variables in patients with diffuse axonal injury.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Predicted outcome scores from diffusion tensor tractography analysis.
Number of subjects: 12
Study: 16583374

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with 0.2 mg/kg of alpha-galactosidase A (agalsidase-alfa) every 2 weeks for 6 months followed by 12 months of open-label ERT
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 14971605

Group type: EXPERIMENTAL
Intervention: Visual interpretation of SPECT alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Visual interpretation of both SPECT and 3D-SSP
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Automated diagnosis based on 3D-SSP
Number of subjects: 90
Study: 10994682

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy integrated into Day Treatment Program (CBT/DTP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard Day Treatment Program (DTP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (CBT/DTP and DTP)
Number of subjects: 24
Study: 8651251

Group type: EXPERIMENTAL
Intervention: OKT3 induction therapy (5 mg/day IV for 10 to 14 days)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Conventional immunosuppressive regimen (CsA, azathioprine, prednisone)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: OKT3 induction therapy
Number of subjects: 207
Study: 1616360

Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 40
Study: 6085189

Group type: EXPERIMENTAL
Intervention: Secretin plus Thr28Nle31CCK25‐33 (continuous 6-day intravenous infusion)
Number of subjects: 9

Group type: COMPARATOR
Intervention: FAM only (5-fluorouracil, adriamycin, and mitomycin C)
Number of subjects: 9
Study: 31240605

Group type: EXPERIMENTAL
Intervention: Group intervention and individual coaching
Number of subjects: 360
Study: 30409942

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gums, used thrice daily for 2 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CPP-ACP chewing gums, used thrice daily for 2 weeks
Number of subjects: 20
Study: 25987491

Group type: COMPARATOR
Intervention: Combo (Passive + Dryland)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dryland
Number of subjects: 16

Group type: COMPARATOR
Intervention: Combo
Number of subjects: 16
Study: 25123839

Group type: EXPERIMENTAL
Intervention: Tirofiban (intracoronary injection of 10 μg/kg prior to PCI, followed by intravenous infusion at 0.15 μg/kg min)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control (no tirofiban)
Number of subjects: 119
Study: 23313205

Group type: EXPERIMENTAL
Intervention: 20-core biopsy protocol (PB20 group)
Number of subjects: 339

Group type: COMPARATOR
Intervention: 12-core biopsy protocol (PB12 group)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 339
Study: 22013201

Group type: EXPERIMENTAL
Intervention: Rye bran product (RP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Refined white wheat product (WP)
Number of subjects: 17